GVK Biosciences Private Limited, a contract services firm from India has entered into a research cooperation with Bayer Cropscience in the area of early discovery chemistry.
The GVK Bio- Bayer alliance is expected to expedite the search for promising active ingredients for innovative crop protection products.
Under the agreement, Bayer CropScience will integrate GVK BIO capacities in the early part of its Discovery chemistry process.
“We want to further speed up the development of our successful crop protection R&D pipeline and we look forward to working with GVK BIO, Asia’s leading contract research organization”, said Dr. Alexander Klausener, Head of Research at Bayer CropScience AG, at the signing ceremony in Hyderabad.
This cooperation in the area of early discovery chemistry will help Bayer CropScience to further increase efficiency in its research, besides helping Bayer to participate in the quickly developing scientific environment in India, Dr Klausener added.
Agri & Crop Sciences Research is a key focus area for GVK BIO.GVK Biosciences has built world-class capabilities in early Discovery Chemistry, stated Manni Kantipudi, President, GVK Biosciences in a press statement.
In April, GVK Biosciences (GVK Bio) and Chinese Excel PharmaStudies (Excel) have joined hands to offer clinical trial sevices in Asian region – a first-ever alliance between a Chinese and Indian CRO.
The GVK – Bio Excel alliance expects to synergise the strengths of each company and offer clients with services that span India and China.
Under the terms of the arrangement, GVK BIO and Excel will help sponsors conduct and manage Phase II-IV clinical trials, statistical analysis and medical writing. Any India trial for Excel will be carried out by the GVK BIO clinical research team and will be managed by a core project management team of Excel. Similarly, a GVK BIO China trial will be carried out by the Excel team and managed by GVK BIO’s project management team.
Similarly, in October, GVK Biosciences entered into a pact with a modeling and simulation (M&S) consultancy firm Quantitative Solutions to develop and market clinical trial outcome databases.
GVK BIO will distribute globally existing Quantitative Solutions databases in five indications including rheumatoid arthritis & psoriasis, chronic HCV, neuropathic pain, osteoporosis (postmenopausal) and major depression, as per the agreement.
GVK BIO and Quantitative Solutions also plan to jointly develop and market additional databases in schizophrenia, Alzheimer’s and other indications shortly.
The databases capture summary level data for the clinical safety and efficacy outcomes from publicly available data sources.
Meta?analyses involving publicly available clinical data provide valuable insights to drug development and marketing programmes. hoped Dr Jaap Mandema, founder & CEO, Quantitative Solutions.
The clinical trial outcome databases are designed to assist drug development teams conduct comparative efficacy and safety analysis, link/scale biomarkers to clinical outcomes, predict or improve trial outcome, and develop product differentiation strategies.
The databases will be supported by customization and modeling and simulation consulting services provided by GVK BIO and QS, respectively, to ensure maximum flexibility and benefits to the clients, GVK said in a press communique.
Pharmacokinetic, pharmacodynamic M&S are well?recognized powerful tools and this collaboration enables us to develop platforms that will help maximize their utility and value in drug development.
Headquartered at Hyderabad, GVK Biosciences provides a spectrum of services. GVK BIO’s diverse portfolio of more than 100 customers includes Big Pharma companies, Agri & Life?sciences companies,leading biotechs and academic institutions.
Quantitative Solutions, based in California, is a scientific consultancy to the pharmaceutical and biotech industry. Quantitative Solutions develops quantitative models of clinical PK, efficacy and safety data to enable better drug development decisions, including: dose selection, trial design, in?licensing drug evaluation etc.
With expenditures of EUR 649 million in research and development in 2008, Bayer CropScience is one of the leading innovative companies in the agricultural industry. In 2008, the insecticides spirotetramat and the herbicide pyrasulfotole have been launched successfully. Three fungicides – fluopyram, bixafen and isotianil – are scheduled for launch in 2010 and 2011. Three further candidates are at an advanced stage of development.
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer CropScience AG, a subsidiary of Bayer AG with annual sales of about EUR 6.4 billion (2008), is one of the world’s leading innovative crop science companies in the areas of crop protection, non-agricultural pest control, seeds and plant biotechnology.